Kevin Chang

Kevin Chang

Auto-generated profile, based on publicly available information

Kevin Chang

Pritzker School of Molecular Engineering, University of Chicago, Chicago, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AMAslan Mansurov
Aslan Mansurov
PHPeyman Hosseinchi
Peyman Hosseinchi
KCKevin Chang
Kevin Chang
ALAbigail L. Lauterbach
Abigail L. Lauterbach
LGLaura T. Gray
Laura T. Gray
JHJeffrey A. Hubbell
Jeffrey A. Hubbell

3 January 2024 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
ASAnna Slezak
Anna Slezak
KCKevin Chang
Kevin Chang
SHSamir Hossainy
Samir Hossainy
AMAslan Mansurov
Aslan Mansurov
SRStuart J. Rowan
Stuart J. Rowan
Mustafa O.  GulerMustafa O. Guler
Mustafa O. Guler
This review discusses the balance of inflammation in immunity and biomaterials strategies to modulate immunity in cases of imbalance such as autoimmune disease, infection, and cancer. Adapted from “Balanced Energy State”, by BioRender.com (2023).

1 December 2023 in Science Advances
Verified
Journal Article
Open access
SKSeounghun Kang
Seounghun Kang
AMAslan Mansurov
Aslan Mansurov
TKTrevin Kurtanich
Trevin Kurtanich
HCHye Rin Chun
Hye Rin Chun
ASAnna J. Slezak
Anna J. Slezak
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
Cancer immunotherapy is moving toward combination regimens with agents of complementary mechanisms of action to achieve more frequent and robust efficacy. However, compared with single-agent therapies, combination immunotherapies are associated with increased overall toxicity because the very same mechanisms also work in concert to enhance systemic inflammation and promote off-tumor toxicity. Therefore, rational design of combination regimens that achieve improved antitumor control without exacerbated toxicity is a main objective in combination immunotherapy. Here, we show that the combination of engineered, tumor matrix-binding interleukin-7 (IL-7) and IL-12 achieves remarkable anticancer effects by activating complementary pathways without inducing any additive immunotoxicity. Mechanistically, engineered IL-12 provided effector properties to T cells, while IL-7 prevented their exhaustion and boosted memory formation as assessed by tumor rechallenge experiments. The dual combination also rendered checkpoint inhibitor (CPI)–resistant genetically engineered melanoma model responsive to CPI. Thus, our approach provides a framework of evaluation of rationally designed combinations in immuno-oncology and yields a promising therapy.

7 October 2022 in ACS Central Science
Verified
Journal Article
Open access
ASAnna J. Slezak
Anna J. Slezak
AMAslan Mansurov
Aslan Mansurov
MRMichal M. Raczy
Michal M. Raczy
KCKevin Chang
Kevin Chang
AAAaron T. Alpar
Aaron T. Alpar
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
Immune stimulating agents like Toll-like receptor 7 (TLR7) agonists induce potent antitumor immunity but are limited in their therapeutic window due to off-target immune activation. Here, we developed a polymeric delivery platform that binds excess unpaired cysteines on tumor cell surfaces and debris to adjuvant tumor neoantigens as an in situ vaccine. The metabolic and enzymatic dysregulation in the tumor microenvironment produces these exofacial free thiols, which can undergo efficient disulfide exchange with thiol-reactive pyridyl disulfide moieties upon intratumoral injection. These functional monomers are incorporated into a copolymer with pendant mannose groups and TLR7 agonists to target both antigen and adjuvant to antigen presenting cells. When tethered in the tumor, the polymeric glyco-adjuvant induces a robust antitumor response and prolongs survival of tumor-bearing mice, including in checkpoint-resistant B16F10 melanoma. The construct additionally reduces systemic toxicity associated with clinically relevant small molecule TLR7 agonists.

22 December 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
SKSeounghun Kang
Seounghun Kang
AMAslan Mansurov
Aslan Mansurov
TKTrevin Kurtanich
Trevin Kurtanich
HCHye Rin Chun
Hye Rin Chun
ASAnna J Slezak
Anna J Slezak
JHJeffrey A Hubbell
Jeffrey A Hubbell
Background: The use of immune checkpoint inhibitors (CPIs) has become a dominant regimen in modern cancer therapy, however immune resistance induced by tumor-associated macrophages (TAMs) with immune suppressive and evasion properties limits responses. Therefore, the rational design of immune modulators that can control the immune suppressive properties of TAMs and polarize them, as well as dendritic cells (DCs), toward a more proinflammatory phenotype is a principal objective in cancer immunotherapy. Methods: Here, using a protein engineering approach to enhance cytokine residence in the tumor microenvironment, we examined combined stimulation of the myeloid compartment via tumor stroma-binding granulocyte–macrophage colony-stimulating factor (GM-CSF) to enhance responses in both DCs and T cells via stroma-binding interleukin-12 (IL-12). We evaluated tumor responses at the levels of outcome, cellular responses, and cytokine responses in both the tumors and the tumor-draining lymph nodes. We further investigated the potentiation of DC response to IL-12 by GM-CSF stimulation ex vivo. Results: Engineered GM-CSF restored an antitumorigenic tumor myeloid microenvironment otherwise suppressed by TAMs, while engineered IL-12 provided effector signals to T cells, thereby boosting both tumor-resident antitumor macrophage and CD8+ T cell populations. Furthermore, engineered GM-CSF potentiated DC response to IL-12, upregulating DC expression of IL-12 receptor and enhancing their expression of proinflammatory cytokines and chemokines on IL-12 exposure. This resulted in remarkable synergistic efficacy in multiple solid tumor models treated with the dual cytokine combination. The combination therapy also improved the efficacy of CPI in a CPI-resistant genetically-engineered melanoma model and exhibited synergistic antitumor efficacy in a pulmonary metastasis model. Conclusion: Our strategy provides a rational design for combination immunotherapy targeting both myeloid and lymphoid compartments through complementary mechanisms.

6 August 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
SHSamir Hossainy
Samir Hossainy
SKSeounghun Kang
Seounghun Kang
JMJ. Emiliano Gómez Medellín
J. Emiliano Gómez Medellín
AAAaron T. Alpar
Aaron T. Alpar
KRKirsten C. Refvik
Kirsten C. Refvik
JHJeffrey A. Hubbell
Jeffrey A. Hubbell
Versatile technologies that can deliver both RNA and protein payloads could streamline development, simplify manufacturing and expand the capabilities of combination therapies. Here we demonstrate an efficient approach to forming ca. 100 nm polymer vesicles (polymersomes) capable of rapid self-assembly without organic solvents, avoiding the need for post-encapsulation purification. Block copolymers are designed with a lower critical solution temperature that renders them soluble in aqueous medium under standard refrigeration, but they spontaneously assemble at room temperature into large batches of nanoparticles with predictable size and morphology. The nanomaterials are designed with charged and biofunctional moieties to drive payload affinity and in vivo targeting, while both siRNA and proteins can be encapsulated during warming at >75% loading efficiencies. Formulations can be stored in a dry state for greater hydrolytic stability under standard refrigeration and can be diluted directly from the vial, bypassing the need for purification required for high scalability. We use our system for in vivo delivery in protein subunit vaccination, immune tolerance induction and siRNA interference therapy in cancer.